TandemLife is now a part of LivaNova, Learn More Here.
COVID-19 UPDATES:The U.S. Food and Drug Administration (FDA) issued guidance on April 6, 2020 to temporarily expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19) public health emergency. As a result of the guidance, cardiopulmonary devices, including select devices from TandemLife | LivaNova, are now temporarily indicated for ECMO therapy greater than 6 hours. To read the full announcement, click here.
American College of Cardiology’s 68th Annual March 16-18, 2019 | Booth #653 Ernest N. Morial Convention Center | 900 Convention Center Blvd, New Orleans, LA 70130 TandemLife is the only MCS platform to offer a “Time to Decide™” Strategy, enabling simple, accessible, temporary ECLS support in minutes. Stop by Booth #653 to learn more about how